ArticleTherapeutics and clinical risk management2016
High bone turnover elevates the risk of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis.
Article in Therapeutics and clinical risk management, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 60 citations in OpenAlex.
- Age-related differences in BMD response during three years of denosumab treatment.Frontiers in aging · 2026Article
- Two-year outcomes of denosumab treatment for osteoporosis comparing the effects of calcium and vitamin D supplementation.Scientific reports · 2025Article
- Comparative Finite Element Analysis of Denosumab and Bazedoxifene on Pedicle Screw Stability in Osteoporotic Spines.JOR spine · 2025Article
- Refractory Denosumab-induced Hypocalcemia in a High-risk Patient With Osteoblastic Metastatic Prostate Adenocarcinoma.JCEM case reports · 2025Article
- [Changes in circulating levels of calcium and bone metabolism biochemical markers in patients receiving denosumab treatment].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2025Article
- Bone turnover markers as predictors of hypocalcemia in patients with bone metastases receiving denosumab.JBMR plus · 2025Article
- Influence of loop diuretics on denosumab-induced hypocalcaemia in osteoporosis: a retrospective observational analysis.Journal of pharmaceutical health care and sciences · 2024Article
- The potential effect of romosozumab on perioperative management for instrumentation surgery.JOR spine · 2024Article
- Nodakenin Ameliorates Ovariectomy-Induced Bone Loss by Regulating Gut Microbiota.Molecules (Basel, Switzerland) · 2024Article
- Hypocalcemia in Patients With Osteoporosis and Normal Renal Function, Treated With Denosumab, a Retrospective Analysis.Nutrition and metabolic insights · 2024Article
- Changes in Testing and Treatment Methods in Osteoporosis Care.Journal of osteoporosis · 2024Article
- Prevalence of denosumab-induced hypocalcemia: a retrospective observational study of patients routinely monitored with ionized calcium post-injection.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2024Observational
- Morroniside Inhibits Inflammatory Bone Loss through the TRAF6-Mediated NF-κB/MAPK Signalling Pathway.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Humulus lupulus L. Extract Protects against Senior Osteoporosis through Inhibiting Amyloid β Deposition and Oxidative Stress in APP/PS1 Mutated Transgenic Mice and OsteoblastsMolecules (Basel, Switzerland) · 2023Article
- High-Dose Intravenous Iron with Either Ferric Carboxymaltose or Ferric Derisomaltose: A Benefit-Risk Assessment.Drug safety · 2022Article
- Short-term efficacy and safety of zoledronate acid or denosumab in Japanese patients with postmenopausal osteoporosis.Journal of bone and mineral metabolism · 2021Article
- Article
- The effect of denosumab on pedicle screw fixation: a prospective 2-year longitudinal study using finite element analysis.Journal of orthopaedic surgery and research · 2021Article
- Humulus lupulus L. Extract Prevents Ovariectomy-Induced Osteoporosis in Mice and Regulates Activities of Osteoblasts and Osteoclasts.Chinese journal of integrative medicine · 2021Article
- Denosumab-induced hypocalcemia in patients with osteoporosis: can you know who will get low?Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypocalcemia is the most common major adverse event in patients with osteoporosis receiving the bone resorption inhibitor denosumab; however, limited information is available regarding risk factors of hypocalcemia. Therefore, this study aimed to identify the risk factors of hypocalcemia induced by denosumab treatment for osteoporosis. We retrospectively reviewed the records of patients who had received initial denosumab supplemented with activated vitamin D for osteoporosis. Serum levels of the following bone turnover markers (BTMs) were measured at baseline: bone-specific alkaline phosphatase (BAP), total N-terminal propeptide of type 1 procollagen (P1NP), tartrate-resistant acid phosphatase 5b (TRACP-5b), and urinary cross-linked N-telopeptide of type 1 collagen (NTX). Of the 85 denosumab-treated patients with osteoporosis studied, 22 (25.9%) developed hypocalcemia. Baseline serum total P1NP, TRACP-5b, and urinary NTX were significantly higher in patients with hypocalcemia than in those with normocalcemia following denosumab administration (all
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.